1
|
Negru AR, Tiliscan C, Tudor AM, Munteanu DI, Popescu C, Lazar M, Streinu-Cercel A, Arama V, Arama SS. BONE QUALITY IN A YOUNG COHORT OF HIV-POSITIVE PATIENTS. Acta Endocrinol (Buchar) 2019; 15:447-453. [PMID: 32377241 DOI: 10.4183/aeb.2019.447] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
Context In HIV+ patients, several factors related to patient and antiretroviral therapy (ART) could determine early onset of bone mineral density (BMD) disturbances. Objective Evaluation of bone quality according to gender in patients from the HIV Romanian cohort. Design A cross-sectional study in "Prof. Dr. Matei Balş" National Institute for Infectious Diseases, Bucharest between 2016-2018. Subject and Methods We collected data regarding HIV infection, ART history, viral hepatitis co-infections and we calculated patients body mass index (BMI). CD4 cell count, HIV viral load (VL), vitamin-D levels were determined. Dual-energy X-ray absorptiometry (DXA) scans were used to evaluate BMD. Results We enrolled 97 patients with the median age of 26 years. According to the DXA T-scores, 10 males and 8 females had osteopenia and 4 males and 4 females had osteoporosis. According to Z-scores 2 males and 1 female had osteoporosis. Hip DXA T-scores revealed osteopenia in 6 males and 9 females, whereas T and Z-scores showed osteoporosis in 2 males and 3 females. Lumbar spine (LS) T-score diagnosed osteopenia in 9 males and 6 females, while T and Z-scores revealed osteoporosis in 3 males and females. In males, low T-scores were associated with decreased BMI; low LS DXA Z-scores with low vitamin-D levels; low T and Z-scores and LS-BMD with high VL. Conclusions Evaluating bone quality in patients with a long history of HIV infection, multiple factors should be taken into account.
Collapse
Affiliation(s)
- A R Negru
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - C Tiliscan
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - A M Tudor
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - D I Munteanu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - C Popescu
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - M Lazar
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - A Streinu-Cercel
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - V Arama
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| | - S S Arama
- "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.,"Prof. Dr. Matei Balş" National Institute of Infectious Diseases, Bucharest, Romania
| |
Collapse
|
2
|
Rufa M, Antonitsis P, Winkler B, Kiessling AH, Ulrich C, Bennett MJ, Kehara H, Asopa S, Alexopoulos C, Zavaropoulos P, Alexopoulos C, Ganushchak YM, McLean LA, Borrelli U, Antonitsis P, Gifford D, Reineke D, Antonitsis P, Bennett M, Schubel J, Schubel J, Ulrich C, Schaarschmidt J, Tiliscan C, Bauer A, Hausmann H, Asteriou C, Argiriadou H, Deliopoulos A, Gatzos S, Anastasiadis K, Zenklusen U, Döbele T, Kohler B, Grapow M, Eckstein F, May M, Keller H, Diefenbach M, Reyher C, Moritz A, Bauer A, Eberle T, Schaarschmidt J, Lucy J, Hausmann H, Larsen M, Asopa S, Webb G, Wright A, Lloyd C, Takano T, Fujii T, Gomibuchi T, Nakahara K, Ohhashi N, Komatsu K, Ohtsu Y, Terasaki T, Wada Y, Seto T, Fukui D, Amano J, Bennett M, Webb G, Lloyd C, Hakim N, Zografos P, Protopapas E, Zavaropoulos P, Kirvassilis G, Sarris G, Alexopoulos C, Hakim N, Zografos P, Protopapas E, Kirvassilis G, Sarris G, Hakim N, Zografos P, Protopapas E, Zavaropoulos P, Kirvassilis G, Sarris G, Körver E, Yamamoto Y, Weerwind P, Medlam W, Bell J, Bennett R, Bennett R, Turner E, Jagannadham K, Westwood E, Silvestri A, Detroux M, Nottin R, Al-Attar N, Pappalardo A, Gabrielli M, Gripari C, Scala A, Mercurio S, Gustin G, Fasolo D, Deliopoulos A, Gatzos S, Mimikos S, Kleontas A, Grosomanidis V, Kyparissa M, Tossios P, Anastasiadis K, Colah S, Farid S, Irons J, Gilhouly M, Moorjani N, König T, Meszaros K, Sodeck G, Erdoes G, Englberger L, Czerny M, Carrel T, Mimikos S, Kostarelou G, Kleontas A, Deliopoulos A, Gatzos S, Foroulis C, Tossios P, Anastasiadis K, Asopa S, Webb G, Gomez-Cano M, Lloyd C, Xhymshiti A, Ulrich C, Schaarschmidt J, Eberle T, Rufa M, Bauer A, Hausmann H. 1st International Symposium on Minimal Invasive Extracorporeal Circulation Technologies, Thessaloniki, Greece, 13–14 June 2014001EMERGENCY CORONARY ARTERY BYPASS GRAFT SURGERY IN PATIENTS WITH OR WITHOUT ACUTE MYOCARDIAL INFARCTION USING THE MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION002IS THERE A LEARNING CURVE WHEN USING MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION IN CORONARY REVASCULARIZATION PROCEDURES?003MINIMAL EXTRACORPOREAL CIRCULATION ASSURES PERFORMANCE OUTCOME004CORONARY ARTERY REVASCULARIZATION WITH A MINIMAL EXTRACORPOREAL CIRCULATION TECHNIQUE: SHOTGUN ANALYSIS IN A PROSPECTIVE, RANDOMIZED TRIAL WITH THREE DIFFERENT PERFUSION TECHNIQUES005EFFECTS OF CELL SALVAGED AND DIRECTLY RETRANSFUSED MEDIASTINAL SHED BLOOD ON THE POSTOPERATIVE COMPETENCY OF THE COAGULATION SYSTEM AFTER CORONARY ARTERY BYPASS GRAFT SURGERY006THE RELATIVE INFLUENCE OF MINIATURIZED CARDIOPULMONARY BYPASS AND OTHER PERIOPERATIVE FACTORS ON BLOOD TRANSFUSION REQUIREMENT AFTER HEART SURGERY007LOWER PLATELET AGGREGATION MIGHT REDUCE PERIOPERATIVE BLEEDING IN MINI-CIRCUIT CARDIOPULMONARY BYPASS COMPARED TO CONVENTIONAL CARDIOPULMONARY BYPASS0085-YEAR EXPERIENCE OF BLOOD TRANSFUSION IN CORONARY ARTERY BYPASS GRAFT SURGERY PATIENTS USING MINIATURIZED EXTRACORPOREAL CIRCULATION009PAEDIATRIC CARDIAC EXTRACORPOREAL MEMBRANE OXYGENATION SUPPORT: IMPROVED OUTCOME WITH EVOLVING TECHNOLOGY AND PRACTICE REFINEMENTS OVER 16 YEARS010THE USE OF ARTERIOVENOUS PCO 2DIFFERENCE (Delta PCO 2) AS AN INDEX OF THE DENSITY OF CAPILLARY PERFUSION DURING PAEDIATRIC CARDIOPULMONARY BYPASS AND EXTRACORPOREAL MEMBRANE OXYGENATION011‘ETERNAL ECMO’: THE CHALLENGE OF PROLONGED POST-CARDIOTOMY EXTRACORPOREAL MEMBRANE OXYGENATION012A VERSATILE MINIMIZED SYSTEM: THE STEP TOWARDS SAFE PERFUSION013HOW WE DEVELOPED A SAFER MINI BYPASS SYSTEM WITH THE USE OF A STOCKERT HEART LUNG BYPASS MACHINE AND MEDTRONIC FUSION OXYGENATOR014MINIMALIZING THE CARDIOPULMONARY BYPASS CIRCUIT AND THE CONSOLE015IS THREE-STAGE VENOUS CANNULA SUPERIOR TO DUAL-STAGE DURING SURGERY WITH MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION?016BENEFITS OF CLOSED MINIATURIZED CARDIOPULMONARY BYPASS017COGNITIVE BRAIN FUNCTION AFTER CORONARY BYPASS GRAFTING WITH MINIMIMAL INVASIVE EXTRACORPOREAL CIRCULATION018MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION REDUCES GASEOUS MICROEMBOLI AND PRESERVES NEUROCOGNITIVE FUNCTION: A SINGLE-CENTRE PROSPECTIVE RANDOMIZED STUDY019THE INFLUENCE OF PERIOPERATIVE FACTORS TO GENERATE ‘OUTLIERS’ IN CARDIAC SURGERY ASSOCIATED ACUTE KIDNEY INJURY: A PRELIMINARY INVESTIGATION INCLUDING DIABETES AND METHOD OF CARDIOPULMONARY BYPASS020MINIMAL INVASIVE EXTRACORPOREAL CIRCULATION IN 64 COMPLEX CARDIAC PROCEDURES: IS IT FEASIBLE AND SAFE? Interact Cardiovasc Thorac Surg 2014. [DOI: 10.1093/icvts/ivu292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
3
|
Arama V, Munteanu DI, Streinu Cercel A, Ion DA, Mihailescu R, Tiliscan C, Tudor AM, Arama SS. Lipodystrophy syndrome in HIV treatment-multiexperienced patients: implication of resistin. J Endocrinol Invest 2014; 37:533-9. [PMID: 24532267 DOI: 10.1007/s40618-014-0057-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/08/2014] [Accepted: 01/25/2014] [Indexed: 02/07/2023]
Abstract
BACKGROUND Impaired production of adipocytokines is a major factor incriminated in the occurrence of lipodystrophy (LD). OBJECTIVE To evaluate LD prevalence and subtypes in HIV treatment-multiexperienced patients, and to determine the correlations between adipocytokines and LD subtypes. METHODS Cross-sectional study in a Romanian tertiary care hospital, between 2008 and 2010, in HIV-positive patients, undergoing cART for ≥6 months. LD diagnosis, based on clinical and anthropometric data, was classified into lipoatrophy (LA), lipohypertrophy (LH) and mixed fat redistribution (MFR). Blood samples were collected for leptin, adiponectin and resistin assessments. RESULTS We included 100 patients, 44 % with LD, among which LA had 63 %. LA patients had sex ratio, median age, treatment duration and median number of ARV regimens of 1, 20, 93 and 3.5 compared to non-LD patients: 1.65, 31, 44 and 1. LH and MFR patients were older and had higher total and LDL cholesterol versus non-LD patients. For both overall group and female group, LA was associated in univariate and multivariate analysis with increased resistin (p = 0.02 and 0.04) and number of ARV regimens (p < 0.001). Determination coefficient (Nagelkerke R (2)) of increased resistin and the number of ARV combinations in the presence of LA was 33 % in overall group and 47 % in female patients. CONCLUSIONS In our young HIV-positive population, LD had high prevalence with predominance of LA subtype. LA was associated with high resistin levels and greater number of ARV regimens in overall group and female subgroup. Resistin could be used as a marker of peripheral adipose tissue loss and might be used as a target for new anti-LD therapeutic strategies.
Collapse
Affiliation(s)
- V Arama
- National Institute of Infectious Diseases, No 1Grozovici Street, 021105, Bucharest, Romania
| | | | | | | | | | | | | | | |
Collapse
|